A Bispecific Antibody is basically what Genetech engineered to cross the blood-brain barrier.
In other recent studies peptides often act in the second arm of similar structures - and of course peptides are also sometimes used in generating antibodies.
Wether Phylogica is directly involved in that outcome is still a speculative presumption - but i guess it also says while not much information is out their in regards to Phylogicas work in bispecific antibodies it could well play a role.
Here's a piece from Genetech in commenting on them after BBB -
"We're about to see a wave of bispecific antibodies," says Ryan Watts, a neurobiologist at Genentech, a biotechnology firm based in San Francisco, California, that pioneered the development of therapeutic antibodies and is now a division of the Swiss pharmaceutical giant, Roche. "They are the hot topic in the field."
PYC Price at posting:
6.7¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)